Abstract
Therapy based on monoclonal antibodies (mAbs) might induce unwanted immunogenicity, which may lead to minor problems, such as injection-site reactions or flu-like symptoms, or to more serious problems, such as anaphylaxis or loss of drug efficacy. Two recent manufacturer-supported reports describe antidrug-antibody formation in patients exposed to mAb-based proprotein convertase subtilisin–kexin type 9 (PCSK9) therapies. Ridker and colleagues reported data from six studies on approximately 4000 patients randomized to the experimental PCSK9 inhibitor bococizumab (a “humanized” …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
